Annotation Detail

Information
Associated Genes
RET
Associated Variants
RET UNKNOWN
RET FUSION
Associated Disease
lung non-small cell carcinoma
Source Database
CIViC Evidence
Description
RET rearrangements are found in 1-2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. An open-label, two-stage, single-centre, phase 2, single-arm trial in the USA in metastatic/unresectable lung cancer harbouring RET rearrangement. 26 Patients were given 60 mg of cabozantinib orally per day. The primary objective was overall response, 25 patients assessable. KIF5B-RET was the predominant fusion in 16 (62%) patients. With confirmed PR seen in 7/25 (28%) response-assessable patients. The reported activity of cabozantinib in patients with RET-rearranged lung cancers defines RET rearrangements as actionable drivers in patients with lung cancers
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/4847
Gene URL
https://civic.genome.wustl.edu/links/genes/42
Variant URL
https://civic.genome.wustl.edu/links/variants/1687
Rating
3
Evidence Type
Predictive
Disease
Lung Non-small Cell Carcinoma
Evidence Direction
Supports
Drug
Cabozantinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
27825636
Drugs
Drug NameSensitivitySupported
CabozantinibSensitivitytrue